Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a clinical study titled ‘A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity’. The study aims to assess the safety and tolerability of AMG 513, a potential treatment for cardiometabolic disease, in individuals with obesity.
The intervention being tested is AMG 513, administered either subcutaneously or intravenously. This drug is designed to address cardiometabolic conditions, with the study testing both single and multiple dose regimens against a placebo.
The study follows a randomized, double-blind, placebo-controlled design. Participants are assigned to receive either the drug or a placebo in a sequential intervention model, with the primary goal being treatment evaluation. Both participants and investigators are blinded to the group assignments.
The study began on September 3, 2024, with its primary completion expected in 2025. The latest update was submitted on August 8, 2025, indicating ongoing recruitment and progress.
This study could significantly impact Amgen’s market position by potentially introducing a novel treatment for obesity-related cardiometabolic diseases. Positive results may boost investor confidence and influence Amgen’s stock performance, especially in a competitive industry focused on innovative obesity treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.